Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 892 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Condition Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Essential Oils for Enhancing QOL in ASD

NCT02543203
View directory record Official record
Conditions
Autism Spectrum Disorder, Quality of Life, Sleep, Anxiety
Interventions
Reconnect, Coconut oil Comparator
Biological
Lead sponsor
Jill Hollway
Other
Eligibility
3 Years to 9 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease

NCT00261950
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Sensipar (Cinacalcet HCl)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
16
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 28, 2026, 6:25 AM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

NCT00974974
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389
View directory record Official record
Conditions
Cocaine Abuse and Dependence
Interventions
Donepezil, 5 mg daily, Oral Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sunscreen Based on Bioadhesive Nanoparticles

NCT02668536
View directory record Official record
Conditions
Melanoma, UV Ray Skin Damage
Interventions
Standard Sunscreen, BNP
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 28, 2026, 6:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Coaching and Leadership in Autism Support Settings

NCT07276750
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD)
Interventions
RUBIES, HELM, Educator Psychoeducation
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
5 Years and older
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
26
States / cities
Duarte, California • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

NCT00109577
View directory record Official record
Conditions
Bipolar Disorder
Interventions
MCN36 (nutritional supplement), Placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Not applicable Interventional

Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety

NCT03837392
View directory record Official record
Conditions
Post Partum Depression, Perinatal Depression, Post Partum Anxiety, Perinatal Anxiety
Interventions
Baseline Assessment (18-26 weeks pregnant), Online Intervention and Phone Coaching Interventions, Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum, Follow Up Assessments: 8 weeks postpartum
Diagnostic Test · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 28, 2026, 6:25 AM EDT
Not yet recruiting Not applicable Interventional

DecNef for Auditory Verbal Hallucinations (AVH) in Schizophrenia

NCT07779226
View directory record Official record
Conditions
Schizophrenia Disorder, Schizoaffecitve Disorder
Interventions
Decoded Neurofeedback
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

NCT00865215
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nicotinamide, Placebo Comparator
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Irvine, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 28, 2026, 6:25 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
79
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

NCT03119363
View directory record Official record
Conditions
Multiple Myeloma, Fatigue
Interventions
AYO light glasses (Experimental), AYO light glasses (Comparator)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 28, 2026, 6:25 AM EDT
Completed No phase listed Observational

Long Term Follow Up KET-PD

NCT06164756
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
Cognitive Behavior Therapy (CBT), Treatment As Usual (TAU)
Other
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

NCT00632229
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Paliperidone, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
St. Petersburg, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 28, 2026, 6:25 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 28, 2026, 6:25 AM EDT
Recruiting Phase 2 Interventional

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
Drug
Lead sponsor
PhenoNet, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone in Early Parkinson's Disease

NCT01280123
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pioglitazone, placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

NCT01885936
View directory record Official record
Conditions
Pompe Disease
Interventions
Albuterol, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 28, 2026, 6:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

NCT03547167
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
38
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 28, 2026, 6:25 AM EDT